Bosulif (bosutinib) prior authorization/notification policy
UnitedHealthcare prior authorization/notification policy specifying clinical coverage criteria, authorization durations, pediatric auto-approval, and reauthorization requirements for Bosulif (bosutinib) for CML, Ph+ ALL, myeloid/lymphoid neoplasms with eosinophilia and other NCCN-recognized regimens. Effective for commercial pharmacy clinical program.
Annual review 2/2025 with no changes to coverage criteria; updated background and references.
Coverage Summary
Coverage stance: Covered with criteria. Scope: UnitedHealthcare prior authorization/notification policy for Bosulif (bosutinib) for commercial pharmacy clinical program covering CML, Ph+ ALL, myeloid/lymphoid neoplasms with eosinophilia and other NCCN-recognized regimens. Effective date: 5/1/2025. Authorization duration when criteria met: 12 months. Covered indications listed in the policy: 4. Pediatric auto-approval: prescriptions for members aged ≤19 years will automatically process without a coverage review. Background: Bosulif is FDA-indicated for adult and pediatric patients ≥1 year with chronic phase Ph+ CML (newly diagnosed or resistant/intolerant) and for adults with accelerated or blast phase Ph+ CML resistant/intolerant to prior therapy.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.